beats by dr dre studio black year

Boston scientific unit cheap beats by dre sale seen cheap beats uk as long Reuters confirmed on thursday that the company, struggling from a costly product recall and still under a mountain of debt in the wake of its 2006 acquisition of guidant corp, is exploring the possibility of Selling its pain management and neurovascular intervention businesses. "I don't want to say they're desperate to Sell, so i'll say there is a great need to do it,"Goldman sachs analyst davidRoman said in an interview, noting that its 2011 liabilities outweigh sources of cash. "For all we know,(Ceo ray elliott)May have bankers breathing down his neck,"Roman said. "I don't think this a proactive change in strategy for him.I just think it's the reality of the situation. "Shares of boston scientific, which generates more than half its revenue from implantable heart rhythm devices and heart stents, fell 1.3 percent on Friday after rising initially when the news was first reported late on Thursday.The company's pain management, or neuromodulation, business is widely viewed as the more attractive of the two because of its potential future growth.The neurovascular intervention business makes devices to treat vascular diseases of the brain and generated sales of $348 million last beats by dr dre studio black year.Analysts say the unit could fetch $800 million to $1 billion.Selling these two units could raise net proceeds of $2.2 billion to $2.4 billion for Boston Scientific, according to JP Morgan analyst Michael Weinstein.Neuromodulation using electrical pulses to stimulate the spinal cord or even the brain is among the most dynamic and fastgrowing areas of the medical technology sector.Jude are seen as possible bidders for the neurovascular intervention business.Analysts say the move illustrates how stretched the company really is.Boston scientific needs to refinance $2.4 billion in 2011 and many fear the company will breach its covenants if it does not do something to raise cash.The company's shares hit a year low of $6.31 last month on news of the ICD recall, and have lost nearly half their value since trading at $11.77 last August.On friday, the shares traded at $6.89.Roman noted that in the past, management had characterized the neuromodulation business as an important strategic growth business.With the exception of its endosurgery business, boston scientific is losing share in the remaining businesses, said roman, who has a"Sell"Rating on the shares.Rick wise, an analyst with leerink swann, said divesting neuromodulation would be a surprise to him since it is one of the fastest growing businesses in boston scientific's portfolio. "Selling neuromodulation could indicate a shift in portfolio strategy by current ceo ray elliott, as boston scientific potentially narrows its end market reach and focuses on stabilizing its larger franchises,"Wise said in a research note.